TMTakeshi Matsui

Takeshi Matsui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Matsui has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Guidance for Liver Rehabilitation in Chronic Liver Disease

    by Shuji Terai, Hiroteru Kamimura, Yoichi Hiasa, Norio Akuta, Toru Ishikawa, Yuichiro Eguchi, Hironao Okubo, Takumi Kawaguchi, Miwa Kawanaka, Tatsuo Kanda, et al.

    In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction‐associated steatotic liver disease (MASLD), liver cirrhosis, and hepatocellular carcinoma (HCC). Specifically, we outline the following: (1) the definition of liver rehabilitation and its target population; (2) exercise therapy in liver rehabilitation according to disease state; (3) considerations for patients with complications; (4) nutritional therapy in liver rehabilitation; and (5) potential economic benefits. Liver rehabilitation represents a novel therapeutic approach for patients with chronic liver disease, and this guidance aims to promote high‐quality clinical research and strengthen the evidence base for its application.


  • Potential indications for liver transplant in Child–Pugh A and Model for End‐stage Liver Disease exception for hepatocellular carcinoma in Japan

    by Ryoichi Goto, Tsuyoshi Shimamura, Tomoaki Nakajima, Koji Ogawa, Kazunari Tanaka, Takao Shimizu, Ryosuke Minami, Takeshi Matsui, Noriyuki Akutsu, Shigeru Sasaki, et al.

    Aim: In 2019, expanded criteria for hepatocellular carcinoma (HCC), known as 5‐5‐500 (size ≤5 cm, number ≤5, alpha‐fetoprotein ≤500 ng/mL), as well as Model for End‐stage Liver Disease (MELD) exception, were implemented in Japan. In the present study, we evaluated liver transplantation indications and the Japanese allocation policy for HCC.Methods: Adults with HCC were evaluated between January 2013 and December 2017 in a multicenter study in Japan. The patients were aged ≤65 years, in line with the limits of Japanese transplant center limits.Results: HCC patients (n = 289) were classified as Child–Pugh A (74%), B (18%), or C (8%). Of these, 178 (62%) and 185 (64%) met the Milan and 5‐5‐500 criteria, respectively. The respective 1‐ and 5‐year overall survival rates of patients who met the criteria were 100% and 88.1% in Child–Pugh A, 91.7% and 30.6% in B, and 72.9% and 0% in C without access to liver transplantation. For Child–Pugh A patients, we developed a risk score using the Child–Pugh score, des‐gamma‐carboxy prothrombin, tumor‐node‐metastasis stage grade, as well as albumin‐bilirubin and albumin‐bilirubin tumor‐node‐metastasis stage , which predicted worse prognosis. Additionally, we showed the characteristics of patients who achieved MELD exception points high enough to receive an organ: survival at least 2 years after waitlist registration, relatively good liver functional reserve, and sufficient tumor control with multiple treatments.Conclusions: High‐risk patients, identified by our scoring system and albumin‐bilirubin tumor‐node‐metastasis stage ≥2 in Child–Pugh A, should be considered for liver transplantation eligibility. The allocation policy for HCC should be revised based on precise evaluations on a regular basis.


  • Open Access

    Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers

    by Kwang Su Kim, Masashi Iwamoto, Kosaku Kitagawa, Hyeongki Park, Sanae Hayashi, Senko Tsukuda, Takeshi Matsui, Masanori Atsukawa, Kentaro Matsuura, Natthaya Chuaypen, et al.

    Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA. Here, we employed a recently developed multiscale mathematical model describing intra- and intercellular viral propagation and applied it in HBV-infected patients under treatment. We developed a model that can predict intracellular HBV dynamics by use of extracellular viral markers, including HBsAg, HBV DNA, and HBcrAg in peripheral blood. Importantly, the model prediction of the amount of cccDNA in patients over time was confirmed to be well correlated with the data for quantified cccDNA by paired liver biopsy. Thus, our method combining classic and emerging surrogate markers enables us to predict the decay dynamics of cccDNA in patients undergoing treatment.


  • Open Access

    Prediction of elimination of intrahepatic cccDNA in hepatitis B virus-infected patients by a combination of noninvasive viral markers

    by Kwang Su Kim, Masashi Iwamoto, Kosaku Kitagawa, Sanae Hayashi, Senko Tsukuda, Takeshi Matsui, Masanori Atsukawa, Natthaya Chuaypen, Pisit Tangkijvanich, Lena Allweiss, et al.

    Evaluation of intrahepatic covalently closed circular DNA (cccDNA) is a key for searching an elimination of hepatitis B virus (HBV) infection. HBV RNA and HBV core-related antigen have been proposed as surrogate markers for evaluating cccDNA activity, although they do not necessarily estimate the amount of cccDNA. Here, we developed a novel multiscale mathematical model describing intra- and inter-cellular viral propagation, based on the experimental quantification data in both HBV-infected cell culture and humanized mouse models. We applied it to HBV-infected patients under treatment and developed a model which can predict intracellular HBV dynamics only by use of noninvasive extracellular surrogate biomarkers. Importantly, the model prediction of the amount of cccDNA in patients over time was confirmed to be well-correlated with the liver biopsy data. Thus, our noninvasive method enables to predict the amount of cccDNA in patients and contributes to determining the treatment endpoint required for elimination of intrahepatic cccDNA.

  • Is it necessary to revise the liver transplantation guidelines to meet the current situation?

    by Takeshi Matsui, Sanae Hayashi, Yasuhito Tanaka

  • Novel strategies for the early diagnosis of hepatitis B virus reactivation

    by Takako Inoue, Takeshi Matsui, Yasuhito Tanaka

    Hepatitis B virus (HBV) reactivation under systemic chemotherapy or immunosuppressive therapy is a serious complication among HBV‐resolved patients. Some medications, such as more than 2 weeks of corticosteroid therapy, can influence HBV reactivation; therefore, screening tests that measure hepatitis B surface antigen (HBsAg), hepatitis B core antibody, and hepatitis B surface antibody before therapy are required. Additionally, because HBV reactivation has been reported in patients positive for HBsAg treated with immune checkpoint inhibitors (ICIs), the prophylactic administration of nucleos(t)ide analogues prior to administering ICIs is recommended for HBsAg‐positive patients. Under these circumstances, highly sensitive novel biomarkers are expected to be used for the early diagnosis of HBV reactivation. A fully automated high‐sensitivity HBsAg assay (detection limit: 5 mIU/ml) by Lumipulse HBsAg‐HQ, with 10‐fold higher sensitivity than that of conventional assays, is currently used. Furthermore, ultra‐sensitive HBsAg assays using a semi‐automated immune complex transfer chemiluminescence enzyme immunoassay (ICT‐CLEIA; detection limit: 0.5 mIU/ml) have been developed. Recently, a fully automated, novel high‐sensitivity hepatitis B core‐related antigen assay (iTACT‐HBcrAg; cut‐off value: 2.1 Log U/mL) has been developed and reported. The utility of ICT‐CLEIA and iTACT‐HBcrAg for the diagnosis of HBV reactivation appears comparable to the use of HBV DNA. In this review, we provide the latest information related to medications that influence HBV reactivation and recently developed novel biomarkers that predict and monitor HBV reactivation.


  • Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma

    by Takeshi Matsui, Susumu Hamada‐Tsutsumi, Yutaka Naito, Masanori Nojima, Etsuko Iio, Akihiro Tamori, Shoji Kubo, Tatsuya Ide, Yasuteru Kondo, Yuichiro Eguchi, et al.

    Aim The microRNA clusters, miR-183/96/182 and miR-217/216a/216b, are significantly upregulated in non-viral hepatocellular carcinoma (NBNC-HCC). Here, we investigate the impact of each member of these clusters on the clinical outcome of NBNC-HCC and analyze the antitumor effects of miR-96-5p. Methods The association between recurrence-free survival of 111 NBNC-HCC patients and the levels of miR-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, miR-216a-5p, and miR-216b-5p in tumor and adjacent tissues was investigated. The impact of miR-96-5p on apoptosis and invasion of a hepatoma cell line, HepG2, was investigated by cell counting, transwell assay and flow cytometry, respectively. Results miR-183-5p, miR-96-5p, miR-182-5p, miR-217-5p and miR-216b-5p were significantly upregulated in tumor tissues compared to the adjacent tissues (p = 0.0005, p = 0.0030, p = 0.0002, p = 0.0011 and p = 0.0288, respectively). By multivariate Cox regression analysis, high tumor/adjacent ratios of miR-182-5p (p = 0.007) and miR-217-5p (p = 0.008) were associated with poor recurrence-free survival. In contrast, a low tumor/adjacent ratio of miR-96-5p (p < 0.001) was associated with poor recurrence-free survival. It suggested that further upregulation of miR-96-5p in tumors may have an inhibitory effect on recurrence. Transfection of miR-96-5p mimic significantly induced apoptosis of HepG2 cells, in association with downregulation of NPM1 and a decrease of phosphorylated AKT protein. Interestingly, simultaneous knockdown of the NPM1 and AKT genes induced apoptosis. miR-96-5p also suppressed proliferation and invasion, that inhibited epithelial-to-mesenchymal transition of HCC cells. Conclusion miR-96-5p as a tumor suppressor would be valuable to stratify NBNC-HCC patients at high risk of recurrence.


  • THU-494-MicroRNA-96 in non-B non-C hepatocellular carcinoma

    by Matsui Takeshi, Susumu Tsutsumi, Yutaka Naito, Masanori Nojima, Etsuko Iio, Akihiro Tamori, Shoji Kubo, Tatsuya Ide, Yasuteru Kondo, Yuichiro Eguchi, et al.

  • The correlations between HBV markers in sera and HBVcccDNA for genotypes

    by M. Takeshi, K. Jong-Hon, Y. Yasushi, T. Kunihiko, M. Hiroyuki